Forest Laboratories: Performance, Products, Pipeline, Potential

Table of Contents

• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
    • Discontinued Agreements
  • Manufacturing/R&D Infrastructure
  • Products/R&D
  • Employees
• Product Performance Forecasts
• Pipeline Analysis
  • Discontinued R&D Projects
• Conclusions/Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CENTRAL NERVOUS SYSTEM

• Marketed Products
  • Campral
  • Celexa
  • Combunox
  • Lexapro
  • Namenda
  • Others
• R&D Projects
  • mGLUR1/5 antagonists
  • Milnacipran
  • Neramexane
  • RGH-188
  • RGH-896
• Growth Forecast

CARDIOVASCULAR

• Marketed Products
  • Benicar
  • Others
• R&D Projects
  • Desmoteplase
  • Nebivolol
• Growth Forecast

OTHER

• Marketed Products
  • Aerobid
  • Armour Thyroid
  • Cervidil
  • Colomycin
  • Infasurf
  • Levothroid
  • Thyrolar
• R&D Projects
  • Aclidinium
  • Ceftaroline
  • ME1036
  • Oglemilast
• Growth Forecast

APPENDIX 1 - FINANCIA L PER FOR MANCE

• Full Year Results 2006

APPENDIX 2 - KEY COR PORATE EVENTS

APPENDIX 3 - KEY AGRE MENTS

• Almirall Prodesfarma SA
• Aurigene Discovery Technologies Ltd
• BTG Ltd
• Cypress Bioscience Inc
• Daiichi Sankyo
• Gedeon Richter Ltd
• Glenmark Pharmaceuticals Ltd
• INO Therapeutics
• Lundbeck
• Merck KGaA
• Merz Pharma GmbH & Co KGaA
• Mylan Laboratories Inc
• PAION AG
• Recordati
• Procter & Gamble
• Samaritan Pharmaceuticals Inc

APPENDIX 4 - INFRASTR UCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHAR MACEUTI CAL

• SUBSI DIARIES

APPENDIX 6 - PRO DUCT INDEX

Index of Tables

• Principal Operating Results
• Sales Breakdown
• Long-Lived Assets
• Major Products, Therapeutic Areas And Sales
• Major Central Nervous System Products, 2006

Index of Charts

• Top Selling Products, 2006
• Campral Sales (2001A-2011E)
• Lexapro Sales (2001A-2011E)
• Namenda Sales (2001-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity